A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Part of paid clinical trials in Newnan, Georgia.
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Study ID
- NCT06116786
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Carcinoma, Non-small-Cell Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- JNJ-86974680 — DRUGJNJ-86974680 will be administered.
- Cetrelimab — DRUGCetrelimab will be administered.
- Radiation Therapy — RADIATIONRadiation therapy will be administered.
Study Details
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Key Dates
- Start date
- Nov 27, 2023
- Status verified
- May 2026
- Primary completion
- Apr 14, 2027
- Completion
- Jun 7, 2029
Study Design
- Enrollment
- 126 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part 1: JNJ-86974680+CetrelimabParticipants will receive JNJ-86974680 alone (dose 1, dose 2, dose 3, and dose 4) daily in 4 cohorts and then along with a set dose of cetrelimab.
- Experimental: Part 2: JNJ-86974680+Cetrelimab+Radiation Therapy (RT)Part 2 will consist of 3 cohorts (A, B and C) and participants will receive treatment with the selected dose of JNJ-86974680 in combination with cetrelimab from part 1, in conjunction with radiation.
Primary Outcome Measure
Number of Participants with Adverse Events (AEs) by Severity [ Time Frame: Up to 2 years 5 months ]
Central Contacts
- Study Contact844-434-4210
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope 1 | Newnan | Georgia | 30265 | - |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | - |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | - |
| Herbert Irving Comprehensive Cancer Center Columbia University Medical Center | New York | New York | 10032 | - |
| Providence Portland Medical Center | Portland | Oregon | 97213 | - |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | - |
| Next Virginia | Fairfax | Virginia | 22031 | - |
Find similar trials in Newnan, GA
By research site
City of Hope 1· Newnan, GAHackensack University Medical Center· Hackensack, NJRoswell Park Comprehensive Cancer Center· Buffalo, NYHerbert Irving Comprehensive Cancer Center Columbia University Medical Center· New York, NYProvidence Portland Medical Center· Portland, ORThomas Jefferson University· Philadelphia, PA
Related Studies
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Birmingham, Alabama
- A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaPHASE2 · Recruiting · Lantern Pharma Inc. · Beverly Hills, California